Paragraphs

PROVEN PERFORMANCE ACROSS THREE PIVOTAL STUDIES

The PRECISE and PRECISE II trials investigated the system’s accuracy, longevity and safety, along with glycemic control data and self-reported quality of life. The PRECISION study captured additional data on safety and accuracy. Combined, the three studies supported the clinical efficacy of Eversense and its exceptional long-term accuracy and wear time.

 
Selector Id
evidence-block-one
Selector Class
evidence-block-one

The PRECISE (European) Trial

Performed over 180 days at 7 clinical sites in Europe, it studied a group of 71 adults with Type 1 and Type 2 diabetes using the Eversense CGM System at home and in the clinic...

Selector Id
evidence-block-two
Selector Class
evidence-block-two

The PRECISE II (U.S.) Trial

The second study (PRECISE II), performed in the United States, investigated the efficacy and safety of the Eversense CGM System during 90 days of continuous sensor wear...

Selector Id
evidence-block-three
Selector Class
evidence-block-three

The PRECISION Trial

This trial was designed to provide additional data on the Eversense CGM system across three metrics...

Selector Id
evidence-block-four
Selector Class
evidence-block-four
 
Selector Id
cgm-image
Selector Class
cgm-image